The first two patients with Alzheimer’s disease have been dosed with Cassava Sciences’ investigational small molecule PTI-125 in a new Phase 2b clinical study. PTI-125 is a small molecule that has been designed to bind to an abnormal form of a protein called Filamin A (or FLNA),…
NeuroEM Therapeutics‘s MemorEMTM — a head-worn device that uses electromagnetic waves — has shown promising results in a preliminary clinical trial of people with mild-to-moderate Alzheimer’s disease. Seven of eight participants demonstrated improved memory after two months of treatment. The results, “A Clinical Trial of Transcranial Electromagnetic Treatment…
Two global Phase 3 clinical trials — MISSION AD1 (NCT02956486) and MISSION AD2 (NCT03036280) — evaluating elenbecestat as a potential therapy for early Alzheimer’s disease are being stopped early, Eisai and Biogen announced. This decision was based on a safety review conducted by an independent data…
AXON Neuroscience’s investigational AADvac1 vaccine against tau protein, a hallmark of Alzheimer’s disease, was found safe and effective at lessening signs of neurodegeneration in patients with mild Alzheimer’s, according to the results of a Phase 2 trial. Among younger study participants, the vaccine also seemed to improve certain cognitive…
An investigational Alzheimer’s treatment called bryostatin-1 failed to meet its primary goal — lesser evidence of dementia in people with more severe disease — in a Phase 2 clinical trial, Neurotrope, the company developing the therapy, announced in a press release. Bryostatin-1 is a molecule that activates protein…
The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for their…
PTI-125, Cassava Sciences’ lead therapeutic candidate for the treatment of Alzheimer’s disease, significantly reduced the levels of disease biomarkers, brain inflammation, and neurodegeneration after 28 days of treatment, top-line data from a Phase 2 trial show. “Based on these encouraging biomarker results, this new treatment could be…
The first patient enrolled in the ADvance II Study has been implanted with a deep brain stimulation (DBS) device to start treatment for mild Alzheimer’s disease. The study will evaluate the safety and effectiveness of stimulating the fornix (DBS-f) — a major inflow and output pathway…
A modified Mediterranean-ketogenic diet can regulate bacteria in the gut that may contribute to the development and progression of cognitive impairment and Alzheimer’s disease, results from a pilot study suggest. Those findings come from a small study by researchers at Wake Forest School of Medicine, which was published in…
With the goal of warding off Alzheimer’s disease through integrative medicine, the Alzheimer’s Research and Prevention Foundation (ARPF) will host its third Brain Longevity Therapy Training and Symposium Oct. 24-27 in Scottsdale, Arizona. The Brain Longevity Specialist certification program, which includes yoga training and other techniques, is a…
Get regular updates to your inbox.